Noticing a trend that each new institutional investor is one-upping the prior institution.
CVI also got in right after the deadline for voting in the annual shareholder meeting.
Come to think of it, the public offering was timed so that any new large institutions would get in after the vote cut-off deadline for this year's shareholder meeting. Clever.
Just Kidding. Happy Holidays.
I'm starting to think Germany's obnoxious foot-dragging on L is slowing data release on Direct. I think the results on Direct will be better than L, so you can see the dilemma here. Roche, a Swiss manufacturer and NWBO competitor may have a bit too much influence on nearby Germany. Just a hunch. Why is everyone almost content to push back Direct results into next year, when Linda said they may come out this quarter? Roche could buy IMUC, market it better than NWBO can market NWBO's own superior products, and cause trouble for patients and investors alike. If Direct results are good, NWBO should not monkey around. Instead they should get out in front with earlier announcements.
Austin, thanks for catching this earlier. Your clear response surpassed what I may have attempted.
I think they have good direct results due to their November 21, 2013 prospectus confirming they are in various levels of preparation in the U.S. and EUROPE.
They also confirmed they are expanding manufacturing capacity for direct in both places.
I do agree they should release some data sooner than later. Yet another reason for this is to avoid some intervening global disturbance like the 2008-2009 crash which set many research projects back years.
Announcing sooner would lessen the likelihood of getting shuffled in the next global major event.
Quite the contrary my dear Watson. Galena did the same type of fund raising before they announced good news about 2 months ago. Look at its price action, fund raising and events from September 1, 2013 to today. Its a way to reward some players, get the float higher so the good news doesn't artificially jack the stock unreasonably high, raise funds from true investors, and it gives credibility to the forthcoming good news -- instead of people questioning whether the good news was 'sexed up' to feed the offering.
Look at their timeline from July 26-27 regarding their announcement schedule for 2013 -- 2014. Most of us are trying to take the dips as buying opportunities, the dilutions as badges of honor, and hope our investments help the company and reward us in the mid-long-term range. Timing is not everything. They are starting to stay on schedule, and are flush with cash. You would be fortunate to get in much lower, unless some bears jerk it around before the next announcement -- but that's part of the ride.
I agree with posiedon59. I posted a while back I thought many attacks bordered on slander...."border" was probably an understatement.
And we already know from their November 21 SEC filing that they are currently in various phases of clinical trial preparation for Direct in Europe.
77.7 Thousand Years. The number of years until Thanksgiving falls this late WHILE Hannukah falls this early. 11/27/13 -- 12/5/13.
"We’ve come to expect the Jewish Festival of Lights, aka Hanukkah, to fall near the end of the year. But this year, the Jewish calendar places the start of the eight-night observance on the eve of Thanksgiving. This particular crossover won’t happen again for another [77.7 thousand years] years, so you might as well make the most of this once-in-a-lifetime opportunity to celebrate Thanksgivukkah."
Not only that, but look at Galena as an example. Galena exercised its option to purchase full over-allotment on the 18th of September, and they closed the exercise of the over-allotment three business days later.
For our case, three business days would take us to that little half-day on Friday.
You might want to study Galena From "Friday the 13th" 2013forward.
I'm not plugging Galena....I do not own any.
I think you misunderstand. The secondary was closed the over allotment was exercised. That must be filled. There will be an announcement when the exercised over allotment is closed.
Here is an example:
"PRESS RELEASENovember 5, 2013, 8:08 a.m. ET
Closing of Over-Allotment Options, Receiving Orphan Drug Designations, Release of Clinical Data, and Obtaining Important Patents - Research Report on Galena, Zalicus, Infinity, Stemline and Insmed"